Skip to main content

Table 2 Comparison of oestrogen and progesterone receptor phenotypes with response in a neoadjuvant trial of tamoxifen versus letrozole

From: Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

  Letrozole Tamoxifen  
Phenotype n RR (%) n RR (%) P
ER+/PgR+ 54/85 64 33/81 41 0.005
ER+/PgR- 18/34 53 16/41 39 0.331
ER-/PgR+ 2/4 50 2/2 100 NS
ER-/PgR- 1/12 8 0/16 0 NS
ErbB1 or 2+/ER+ 15/17 88 4/19 21 0.0004
ErbB1 and 2-/ER+ 55/101 54 42/100 42 0.08
ErbB1 or 2+/ER- 0/9 0 0/10 0 -
  1. ER, oestrogen receptor; NS, not significant; PgR, progesterone receptor; RR, response rate. Data from Ellis and coworkers [32].